Treatment News : Merck to Discount Isentress and Crixivan for ADAPs

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » May 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

May 6, 2010

Merck to Discount Isentress and Crixivan for ADAPs

Merck will continue a price freeze on two of its HIV drugs—Isentress (raltegravir) and Crixivan (indinavir)—and the company will offer steeper discounts to state AIDS Drug Assistance Programs (ADAPs), according to an agreement reached with The National Alliance of State and Territorial AIDS Directors (NASTAD). The new price agreement is intended to address a crisis in ADAP funding that has already resulted in waiting lists in a number of states for people with HIV.

“ADAPs provide crucial support for uninsured and underserved people living with HIV,” said Patrick Bergstedt, senior vice president and general manager of Merck’s infectious diseases franchise. “At Merck we believe that it is important that ADAPs are able to continue to provide support for as many people that need it, especially given the unprecedented fiscal challenges confronting many states at this time.”

The integrase inhibitor Isentress is a new HIV drug that was recently added to the list of preferred first-line antiretroviral (ARV) regimens in the U.S. Department of Health and Human Services’ treatment guidelines. Crixivan, one of the first protease inhibitors approved to treat HIV, is less frequently prescribed.

“On behalf of the nearly 200,000 clients that ADAPs serve, we applaud Merck for its continued commitment to HIV,” said Dwayne Haught, manager of the HIV Medication Program for the Texas Department of State Health Services and a spokesperson for the ADAP Crisis Task Force. “Merck’s history of HIV research, along with its responsible pricing and related efforts to help alleviate the current funding crisis facing ADAPs, is consistent with Merck’s track record of working to help ensure access to treatments such as Crixivan and Isentress for the people most in need.”

The ADAP Crisis Task Force has been meeting recently with all of the pharmaceutical companies selling ARVs in hopes of securing similar pricing agreements.

Search: Merck, ADAP, NASTAD, Isentress, raltegravir, Crixivan, indinavir


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    RyGuy00
    New York
    New York


    pevans
    San Francisco
    California


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been tested for hepatitis C?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.